64 results
8-K
EX-10.1
PLX
Protalix BioTherapeutics Inc.
26 Aug 21
Protalix BioTherapeutics Announces Closing of Private Note Exchange
7:16am
8-K
EX-10.2
PLX
Protalix BioTherapeutics Inc.
26 Aug 21
Protalix BioTherapeutics Announces Closing of Private Note Exchange
7:16am
8-K
EX-10.1
vjjl50j953g jx
13 Aug 21
Protalix BioTherapeutics Announces Private Note Exchange
7:05am
8-K
EX-10.1
l50g6tqt
8 Jun 20
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
5:04pm
8-K
EX-10.2
r25bgad uk1y
8 Jun 20
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
5:04pm
8-K
EX-10.1
zb9 re1t5hnplodcweu
12 Mar 20
Protalix BioTherapeutics Announces $43.7 Million in Financing to
8:04am
8-K
EX-10.1
di5s6 gqecx0p54
29 Jul 19
Protalix BioTherapeutics Appoints Eyal Rubin as its New Senior Vice President and Chief Financial Officer
7:09am
8-K
EX-10.1
ebfi7lo
21 May 19
Protalix BioTherapeutics Appoints Dror Bashan as its New President and Chief Executive Officer and Director
7:35am
8-K
EX-10.1
mx8h1n16vg h54x4mhy
25 Jul 17
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
12:00am
8-K
EX-10.2
6d05hwin9boea
25 Jul 17
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
12:00am
8-K
EX-10.1
9e4qeeshj6z l2a
7 Dec 16
Entry into a Material Definitive Agreement
12:00am